WO2024036197A3 - Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome - Google Patents

Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome Download PDF

Info

Publication number
WO2024036197A3
WO2024036197A3 PCT/US2023/071908 US2023071908W WO2024036197A3 WO 2024036197 A3 WO2024036197 A3 WO 2024036197A3 US 2023071908 W US2023071908 W US 2023071908W WO 2024036197 A3 WO2024036197 A3 WO 2024036197A3
Authority
WO
WIPO (PCT)
Prior art keywords
activation
methods
conditions associated
treating diseases
compositions
Prior art date
Application number
PCT/US2023/071908
Other languages
French (fr)
Other versions
WO2024036197A2 (en
Inventor
Roger A. Johns
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2024036197A2 publication Critical patent/WO2024036197A2/en
Publication of WO2024036197A3 publication Critical patent/WO2024036197A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
PCT/US2023/071908 2022-08-09 2023-08-09 Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome WO2024036197A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263370851P 2022-08-09 2022-08-09
US63/370,851 2022-08-09

Publications (2)

Publication Number Publication Date
WO2024036197A2 WO2024036197A2 (en) 2024-02-15
WO2024036197A3 true WO2024036197A3 (en) 2024-05-02

Family

ID=89852492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071908 WO2024036197A2 (en) 2022-08-09 2023-08-09 Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome

Country Status (1)

Country Link
WO (1) WO2024036197A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170276688A1 (en) * 2006-12-18 2017-09-28 The Johns Hopkins University Anti-himf antibodies to treat lung diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170276688A1 (en) * 2006-12-18 2017-09-28 The Johns Hopkins University Anti-himf antibodies to treat lung diseases

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE PROTEIN 10 February 2021 (2021-02-10), ANONYMOUS: "immunoglobulin variable region, partial [Homo sapiens]", XP093168416, Database accession no. QRG33514.1 *
DATABASE PROTEIN 10 September 2012 (2012-09-10), ANONYMOUS: "anti-oligomeric synuclein single-chain Fv antibody D5E [synthetic construct]", XP093168422, Database accession no. AFR23376.1 *
DATABASE PROTEIN 17 September 2019 (2019-09-17), ANONYMOUS: "IGL c3598_light_IGKV1D-39_IGKJ1, partial [Homo sapiens]", XP093168408, Database accession no. QEP13659.1 *
DATABASE PROTEIN 18 May 2021 (2021-05-18), ANONYMOUS: "anti-peanut 2S albumin immunoglobulin heavy chain variable region, partial [Homo sapiens]", XP093168411, Database accession no. QVG74477.1 *
DATABASE PROTEIN 21 December 2020 (2020-12-21), ANONYMOUS: "MAG: Ig-like domain-containing protein [Gemmatimonadetes bacterium]", XP093168421, Database accession no. MBI2407530.1 *
DATABASE PROTEIN 23 July 2016 (2016-07-23), ANONYMOUS: "immunoglobulin heavy chain variable region, partial [synthetic construct]", XP093168415, Database accession no. ABQ50854.1 *
DATABASE PROTEIN 25 July 2016 (2016-07-25), ANONYMOUS: "anti-canine dendritic cell scFv antibody, partial [synthetic construct]", XP093168403, Database accession no. ADP21080.1 *
DATABASE PROTEIN 25 July 2016 (2016-07-25), ANONYMOUS: "anti-TNF alpha single chain Fv antibody, partial [synthetic construct]", XP093168424, Database accession no. AEX15593.17 *
DATABASE PROTEIN 26 July 2016 (2016-07-26), ANONYMOUS: "anti-fluorescein immunoglobulin light chain variable region, partial [Homo sapiens]", XP093168418, Database accession no. CAQ55833.1 *
DATABASE PROTEIN 26 July 2016 (2016-07-26), ANONYMOUS: "immunoglobulin light chain variable region, partial [Homo sapiens]", XP093168405, Database accession no. AAK94805.1 *
DATABASE PROTEIN 28 July 2012 (2012-07-28), ANONYMOUS: "scFV antibody, partial [synthetic construct]", XP093168428, Database accession no. AFN94004.1 *

Also Published As

Publication number Publication date
WO2024036197A2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
AU2017204267B2 (en) Treatment for dupuytren's disease
CY1115456T1 (en) METHOD OF ADJUSTMENT OF ANTI-ANTI-IL-5
KR20210031645A (en) IL-11RA antibody
FR3025518B1 (en) LIGANDS POTENTIATING THE BIOACTIVITY OF GONADOTROPHINS
MX2022001403A (en) Methods of administering anti-siglec-8 antibodies and corticosteroids.
MXPA03011499A (en) Fce fusion proteins for treatment of allergy and asthma.
Qiu et al. Activation of NLRP3 inflammasome by lymphocytic microparticles via TLR4 pathway contributes to airway inflammation
BR112023026111A2 (en) ANTI-CD40 ANTIBODY, ANTIGEN BINDING FRAGMENT AND MEDICAL USE THEREOF
WO2020169698A1 (en) Sensitization of cancer cells to tnf by bet inhibition
KR102120620B1 (en) Treatment of mucositis with immunoglobulin
Mascarell et al. Characterization of oral immune cells in birch pollen‐allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen‐presenting cells
JP2022501356A (en) Use of cathepsin S inhibitors for the formation of anti-drug antibodies
WO2024036197A3 (en) Compositions and methods for treating diseases and conditions associated with activation of the nlrp3 inflammasome
TW202033558A (en) Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
Lang et al. Cholestasis induced liver pathology results in dysfunctional immune responses after arenavirus infection
MX2023009681A (en) Anti-tl1a antibody compositions and methods of treatment in the lung.
MX2024005430A (en) Anti-tau antibody compositions, dosage forms, and methods.
EP3322724B1 (en) Il-26 inhibitors
WO2022091010A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
WO2014153241A1 (en) Treatment of staphylococcal disorders
Wilson et al. Interplay between fat cells and immune cells in bone: Impact on malignant progression and therapeutic response
Xie et al. Anti-coagulation effect of Fc fragment against anti-β2-GP1 antibodies in mouse models with APS
Prayitno The role of COX-2, caspase-1 and IL-17 in pericoronitis-related inflammation due to lower third molar impaction
MX2021008507A (en) Lilrb3-binding molecules and uses therefor.
WO2024133132A9 (en) Anti-tgfbeta receptor 1 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853504

Country of ref document: EP

Kind code of ref document: A2